Uhz Klinische Forschung
- Address
- Unterstrasse 75, Frintrop, 45359 Essen, Germany
Cardiovascular Research
At Uhz Klinische Forschung in Essen, a major focus is cardiovascular disease research, especially atherosclerotic cardiovascular disease, high cholesterol, and elevated lipoprotein(a). These studies are designed to test new ways to lower heart risk, reduce major cardiovascular events, and improve long-term prevention for people with established or high-risk disease.
- Testing new treatments for ASCVD and broader cardiovascular risk reduction
- Studying therapies for hypercholesterolemia, hyperlipidemia, and elevated Lp(a)
- Evaluating whether new approaches can reduce major adverse cardiovascular events
The site is contributing to research that aims to improve both cholesterol control and protection against serious heart and vascular complications.
Metabolic and Weight Management Studies
Another important area at this research site is nutritional and metabolic disease research, with trials in obesity, overweight, and related conditions such as type 2 diabetes. The main goal is to assess new treatments that may support weight loss, improve blood sugar control, and help manage health risks linked to excess body weight.
- Research in obesity and overweight with and without diabetes
- Evaluating treatments that may improve body weight and HbA1c
- Exploring options for people with weight-related health conditions
These studies reflect a strong interest in finding better tools for long-term metabolic health and weight management.
Immune and Infectious Disease Research
The site also supports immune system disease and virus disease research, including studies on herpes zoster and respiratory syncytial virus. These trials focus on understanding immune response, checking protection over time, and evaluating vaccines that may help prevent infection in older adults.
- Vaccine research for herpes zoster prevention
- Studies of RSV immune response and lasting protection
- Assessing vaccine effectiveness in older adult populations
This part of the portfolio emphasizes prevention, immune protection, and better disease control in groups at higher risk of complications.
Respiratory and Sleep-Related Research
Research at Uhz Klinische Forschung includes respiratory tract disease studies, particularly obstructive sleep apnea. These trials are examining whether new therapies can improve breathing-related sleep disruption and reduce the burden of symptoms linked to obesity and other metabolic conditions.
- Trials in obstructive sleep apnea
- Studying treatment effects on sleep-related breathing problems
- Linking respiratory outcomes with overweight and obesity
The work here aims to improve both symptom control and overall quality of life for people affected by sleep and breathing disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uhz Klinische Forschung
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi- center, randomized, double-blind, placebo-controlled parallel–group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated Lipoprotein(a) | Novartis Pharma AG | Phase II | Not Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| HRS 9531 | 2 | Unknown | 2026-06-16 | 2026-06-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.